Comparative efficacy and safety of paricalcitol versus vitamin D receptor activators for dialysis patients with secondary hyperparathyroidism: a meta-analysis of randomized controlled trials

Comparative efficacy and safety of paricalcitol versus vitamin D receptor activators for dialysis patients with secondary hyperparathyroidism: a meta-analysis of randomized controlled trials

Abstract Background Secondary hyperparathyroidism (SHPT) is a severe complication for dialysis patients. Vitamin D receptor activators (VDRAs) are used to treat SHPT, but the comparative efficacy and safety between paricalcitol and other vitamin D receptor activators for management of SHPT in dialys...

Full description

Bibliographic Details
Main Authors: Yifeng Xie, Peiling Su, Yifan Sun, Hongsheng Zhang, Rong Zhao, Liang Li, Lanfen Meng
Format: Article
Language:English
Published: BMC 2017-08-01
Series:BMC Nephrology
Subjects:
Paricalcitol
Vitamin D receptor activator
Secondary hyperparathyroidism (SHPT)
Hemodialysis
Peritoneal dialysis
Online Access:http://link.springer.com/article/10.1186/s12882-017-0691-6

Internet

http://link.springer.com/article/10.1186/s12882-017-0691-6

Similar Items